Skip to content

Fibrosis Assay Services

Inducible disease models using primary human cells.


There have been significant, recent advancements in fibrotic disease therapeutics development, including clinical progression of small molecules and biologics, and more novel modalities and delivery methods, such as siRNA nanoparticles. Fibrosis-targeted therapeutics require robust, high-content, cell-based assays to evaluate efficacy and mechanism of action, but the history of failure of anti-fibrotic therapeutic agents at clinical stages of development suggest that current assays are inadequate for these purposes. These failures may largely be due to the need for a physiologically relevant in vitro model, as most development has been performed in non-human or immortalized cells. To reduce this risk, we use primary human cells to better recapitulate the environment from which fibrotic pathologies originate.

Ready-to-Go Assay Service

Lung Fibrosis

Commonly-used fibrosis assays are often either too low throughput or are poorly predictive of downstream success. Our Lung Fibrosis Assay Service uses primary, normal human fibroblasts (NHLF) cells cultured using a protocol that limits basal induction of fibrosis (which is often observed with routine, cell-culture procedures). This not only allows for enhanced control of fibrotic induction, but also affords a format amenable to higher-throughput therapeutics profiling.

Unique Questions. Unique Solutions.